Fibrocystic_disease_of_the_breast_in_premenopausal_women:_histohormonal_correlation_and_response_to_luteinizing_hormone_releasing_hormone_analog_treatment._Sixty-six_patients_with_fibrocystic_mastopathy_were_enrolled_in_the_trial_after_being_selected_according_to_clinical,_radioultrasonographic,_and_histologic_criteria._No_characteristic_hormonal_profile_was_noted_in_most_patients_(52%)._Estrogen_receptors_or_progesterone_receptors,_or_both,_were_found_in_57%_of_patients._Hormone_receptor_levels_were_correlated_with_atypical_proliferative_mastopathy_(87.5%)._Mastopathy_was_associated_with_a_uterine_fibroma_or_a_fibromatous_uterus_in_73%_of_cases._All_patients_received_intramuscular_injections_of_a_sustained_delivery_system_(microcapsules)_of_luteinizing_hormone_releasing_hormone_agonist_D-Trp6-LHRH,_Ipsen-Biotech,_Paris)_for_3_to_6_months._In_case_of_partial_response_at_3_months,_an_antiestrogen_(tamoxifen,_40_mg/day,_for_estrogen_receptor-predominant_lesions)_or_a_progestin_(cyproterone_acetate,_50_mg/day,_for_progesterone_receptor-predominant_lesions)_was_added_to_the_luteinizing_hormone_releasing_hormone_agonist._A_complete_response_was_observed_in_more_than_half_of_the_patients_(n_=_35,_53%)_treated_by_D-Trp6-LHRH_alone_(n_=_29)_or_associated_with_tamoxifen_(n_=_4)_or_cyproterone_acetate_(n_=_2)._A_significant_partial_response_was_observed_in_30_other_patients_(45%)._Additionally,_half_of_them_received_inhibitory_drugs._The_best_responses_were_seen_with_cyst_reformation_(complete_response,_100%)_and_fibrous_block._Clinical_responses_to_treatment_with_D-Trp6-LHRH_alone_were_independent_of_hormone_receptor_status,_but_synergistic_effects_occurred_with_concomitant_use_of_the_corresponding_inhibitory_drugs._We_conclude_that_chronic_mastopathy,_particularly_when_associated_with_uterine_fibroma,_can_be_successfully_treated_by_luteinizing_hormone_releasing_hormone_analogs_in_premenopausal_women.